Vectus Biosystems Limited
ASX: VBS.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ivan Rajkovic
- Employees
- 5
- Headquarters
- Rosebery, Australia
- IPO year
- 2016
- Market cap
- A$6.7M
- Website
- https://www.vectusbiosystems.com.au
Loading VBS…
Loading profile data…Frequently asked questions about VBS
What does Vectus Biosystems Limited (VBS.AX) do?
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring,...
Where does VBS.AX trade?
Vectus Biosystems Limited (VBS.AX) trades on the Australian Securities Exchange.
What sector is VBS.AX in?
Vectus Biosystems Limited (VBS.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Vectus Biosystems Limited?
Ivan Rajkovic is the chief executive officer of Vectus Biosystems Limited (VBS.AX).
Where is Vectus Biosystems Limited headquartered?
Vectus Biosystems Limited is headquartered in Australia.
Does VBS.AX pay a dividend?
Vectus Biosystems Limited (VBS.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VBS.AX go public?
Vectus Biosystems Limited (VBS.AX) completed its initial public offering in 2016.